(Q33959006)

30 July 2017

1 reference

title

Management of viral hepatitis B. (English)

1 reference

30 July 2017

1 reference

Chutima Pramoolsinsup

series ordinal

1

1 reference

30 July 2017

1 February 2002

1 reference

Journal of Gastroenterology and Hepatology

30 July 2017

1 reference

30 July 2017

17 Suppl

1 reference

30 July 2017

S125-45

1 reference

Epidemiology of hepatitis B virus infection in the Asia-Pacific region

30 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Natural history of hepatitis B virus infection in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Acute hepatitis A and acquired immunity to hepatitis A virus in hepatitis B virus (HBV) carriers and in HBV- or hepatitis C virus-related chronic liver diseases in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Effect of interferon-gamma on hepatitis B viral antigen expression in primary hepatocyte culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Current therapeutic trends in therapy for chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Antiviral therapy of the Asian patient with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Clinical pharmacokinetics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Quantitative assessment of hepatitis B virus DNA during a 24-week course of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Perspectives for the treatment of hepatitis B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Famciclovir in chronic hepatitis B: results of a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Clinical experience with famciclovir against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Clearance of hepatitis B surface antigen after bone marrow transplantation: Role of adoptive immunity transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.17.S1.3.X

10.1046/J.1440-1746.17.S1.3.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

12000599